FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely gynaecology and endocrinology, and can be used for treating polycystic ovarian syndrome, ovarian hyperandrogenism and/or related disorders. Using according to the invention involves an insulin sensitiser for producing a vaginal medicinal product. Methods according to the invention involve the vaginal administration of the insulin sensitiser. Pharmaceutical compositions according to the invention contain the insulin sensitiser for vaginal administration.
EFFECT: using the inventions enables decreasing blood plasma testosterone and atretic follicle count by the direct affect on ovarian tissue with reducing systemic side effects.
13 cl, 5 tbl, 2 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING POLYCYSTIC OVARY SYNDROME | 2020 |
|
RU2757220C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF OVARIAN AND ADRENAL HYPERANDROGENISM IN GIRLS OF PUBERTY AGE | 2015 |
|
RU2592235C1 |
| METHOD FOR TREATING CHRONIC ANOVULATION AND PREVENTING SYNDROME OF OVARIAN HYPERSTIMULATION | 1999 |
|
RU2201225C2 |
| METHOD OF DIAGNOSTICS OF MENSTRUAL DYSFUNCTION AGAINST BACKGROUND OF POLYCYSTIC OVARIAN SYNDROME BY IMMATURE GIRLS | 2013 |
|
RU2535096C1 |
| METHOD FOR ESTIMATING DEGREE OF SEVERITY OF OVARIAN DYSFUNCTION IN GIRLS WITH PUBERAL HYPERANDROGENISM | 2018 |
|
RU2690502C1 |
| METHOD FOR TREATMENT OF POLYCYSTIC OVARY SYNDROME | 2017 |
|
RU2665969C1 |
| TREATMENT OF HEPATIC STEATOSIS RELATED OLIGO-OVULATION | 2016 |
|
RU2745606C2 |
| METHOD OF MODELLING OF POLYCYSTIC OVARIES | 2007 |
|
RU2337411C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS OF METFORMIN AND/OR WEIGHT-LOSS THERAPY IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME | 2010 |
|
RU2427842C1 |
| METHOD OF DERMATOSIS DEVELOPMENT PREDICTION IN WOMEN WITH SCLEROPOLYCYSTIC OVARIAN SYNDROME (SPCO) | 2008 |
|
RU2367954C1 |
